Šalis: Airija
kalba: anglų
Šaltinis: HPRA (Health Products Regulatory Authority)
Ibuprofen
Carysfort Healthcare Limited
M01AE; M01AE01
Ibuprofen
75 milligram(s)
Suppository
Product not subject to medical prescription
Propionic acid derivatives; ibuprofen
Marketed
2012-08-31
PACKAGE LEAFLET: INFORMATION FOR THE USER Tefin 75mg Suppositories Ibuprofen FOR RECTAL ADMINISTRATION ONLY FOR INFANTS Age 8 months up to 3 years CONTAINS IBUPROFEN READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING TEFIN BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU AND YOUR CHILD - Always take this medicine exactly as described in this leaflet or as your pharmacist or doctor has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist or doctor if you need more information or advice. - If you get any side effects, talk to your pharmacist or doctor. This includes any possible side effects not listed in this leaflet (See section 4). - If Tefin is required for three days or if symptoms worsen, you should consult a doctor. IN THIS LEAFLET: 1. What Tefin is and what it is used for. 2. What you need to know before you give Tefin to your child. 3. How to use Tefin. 4. Possible side effects. 5. How to store Tefin. 6. Contents of the pack and further information. 1. WHAT TEFIN IS AND WHAT IT IS USED FOR Tefin contains ibuprofen which is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs are medicines which have pain-relieving (analgesic) effects and also have the effect of reducing inflammation (anti-inflammatory), swelling and temperature. They are also used to soothe away pain from teething, toothache, earache, headache, cold and flu symptoms, sore throats, strains and sprains. Tefin is used in children for the symptomatic treatment of : - mild to moderate pain, - fever. 2. WHAT YOU NEED TO KNOW BEFORE YOU GIVE TEFIN TO YOUR CHILD DO NOT GIVE TEFIN TO YOUR CHILD IF: - your child is allergic (hypersensitive) to ibuprofen or any of the other ingredients of Tefin (see section 6); - in the past your child DEVELOPED ASTHMATIC ATTACKS, swelling of the nasal mucosa or skin reactions after taking aspirin (acetylsalicylic acid /ASA), ibuprofen or other nonsteroidal anti- inflammatory drugs; - your child has a BLOOD COUNT DISORDER; - your child has a HISTORY OF BLEEDING FROM THE STOMA Perskaitykite visą dokumentą
Health Products Regulatory Authority 31 July 2020 CRN009VCF Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tefin 75 mg Suppositories 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 75 mg of ibuprofen. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suppository. White, odourless, torpedo-shaped suppository. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the symptomatic treatment of mild to moderate pain and fever in children of 8 months or older and with body weight of at least 7.5kg. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Posology:_ _ _ _Paediatric population_ Details on the posology are available in the following tables. The dosage of Tefin for children and young persons depends on the patient's age and body weight. In general, the single dose is 7 to 10 milligrams per kilogram body weight and the maximum daily dose 30 milligrams per kilogram body weight. The dosage interval depends on the symptoms and the maximum daily dose and should be at least six hours. If Tefin is required for three days or if symptoms worsen, a doctor should be consulted. Age Body weight Single dose Maximum daily dose 8 to 12 months 7.5 to 10 kilogram 1 Suppository (75 milligram) 3 Suppositories (225 milligram daily) 12 months to 3 years 10 to 15 kilogram 1 Suppository (75 milligram) 4 Suppositories (300 milligram daily) _Method ofadministration and duration oftreatment:_ Tefin suppositories should be put deep into the rectum after bowel movement. They may be warmed up in the hands or dipped for a short time into warm water to improve their sliding properties. The lowest effective dose should be used for the shortest duration necessary to relieve symptoms (see section 4.4) SPECIAL POPULATIONS Elderly patients: No adjustment of dosage is required. Due to possible side-effects (see section 4.4), elderly people should be carefully monitored. Health Products Regulatory Authority 31 July 2020 CRN009VCF Page 2 of 11 Impaired renal function: No reduction of Perskaitykite visą dokumentą